Tempus AI (NasdaqGS:TEM) and Daiichi Sankyo announced a collaboration to use Tempus' AI models in oncology drug development. The partnership centers on a novel antibody drug conjugate program, aiming ...

The initiative will apply its massive, multimodal dataset to build models that aim to improve diagnostic, prognostic, and predictive modeling CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a ...

Tempus AI has gained clearance for software that uses artificial intelligence to identify patients who may have the cardiovascular condition of low left ventricular ejection fraction, or LVEF. The ...

Tempus AI is a healthcare technology company that utilizes artificial intelligence technology to collect and analyze molecular, clinical, and genomic data. It collects clinical and genomic databases ...

New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...

Tempus AI, Inc. (NASDAQ:TEM) is one of the top 10 medical AI companies to buy according to analysts. On July 16, the company confirmed that it had received clearance from the US Food and Drug ...

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software. This software utilises AI to detect individuals with a low left ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the ...

Tempus and New York City-based NYU Langone Health have formed a multi-year strategic collaboration to advance cancer research through molecular profiling and data-driven insights. The partnership will ...

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced the launch of a new program specifically geared towards using ...